Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Virus or bacteriophage
Reexamination Certificate
2006-12-12
2006-12-12
Campell, Bruce R. (Department: 1648)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Virus or bacteriophage
C424S093100, C424S093200, C435S235100, C435S236000, C435S239000, C536S023720, C536S024100
Reexamination Certificate
active
07147848
ABSTRACT:
The present invention is directed to non-pathogenic, oncolytic, recombinant polioviruses for the treatment of various forms of malignant tumors. The recombinant polioviruses of the invention are those in which the internal ribosomal entry site (IRES) of the wild type poliovirus was exchanged with the IRES of other picornaviruses, and optionally P1, P3 or the 3′NTR thereof was exchanged with that of poliovirus Sabin type. More particularly, the present invention is directed to the administration of the non-pathogenic, oncolytic, recombinant poliovirus to the tumor directly, intrathecally or intravenously to cause tumor necrosis. The method of the present invention is particularly useful for the treatment of malignant tumors in various organs, such as: breast, colon, bronchial passage, epithelial lining of the gastrointestinal, upper respiratory and genito-urinary tracts, liver, prostate and the brain. Astounding remissions in experimental animals have been demonstrated for the treatment of malignant glioblastoma multiforme, an almost universally fatal neoplasm of the central nervous system.
REFERENCES:
patent: 5593972 (1997-01-01), Weiner et al.
patent: 5674729 (1997-10-01), Wimmer et al.
patent: 5965124 (1999-10-01), Feinberg et al.
Gromeier et al., Proceedings of the NAtional Academy of Sciences, vol. 97 No. 12, pp. 6803-6808 (Jun. 2000).
Ansardi et al., Cancer Research, vol. 54 No. 24, pp. 6359-6364 (Dec. 1994).
Ansardi et al., Cancer Research, vol. 61 No. 23, pp. 8470-8479 (Dec. 2001).
Tsypkin et al., Cancer, vol. 38 No. 4, pp. 1796-1806 (Oct. 1976).
Alexander et al., Proceedings of the NAtional Academy of Sciences, USA, vol. 91 No. 4, pp. 1406-1410 (Feb. 1994).
Kauder et al., Journal of Clinical Investigation, vol. 113 No. 12, pp. 1743-1753 (Jun. 2004).
Hawkins et al., “Oncolytiv biotherapy, a novel therapeutic platform,” The Lancet Oncology, vol. 3 No. 1, pp. 17-26 (Jan. 2002).
Mandl et al., “Preexisting Immunity to Poliovirus Does Not Impair the Efficacy of Recombinant Poliovirus Vaccine Vectors,” Journal of Virology, vol. 75 No. 2, pp. 622-627 (Jan. 2001).
Gromeier et al., “Intergeneric poliovirus recombinants for the treatment of malignant glioma,” Proceedings of the National Academy of Science, USA, vol. 97 No. 12, pp. 6803-6808 (Jun. 2000).
Sabin & Boulger,J. Biol. Stand.,1:115-118 (1973).
Leibel, S.A., et al.,Cancer,35:1551-1557 (1975).
Walker, M.D., et al.,J. Neurosurg.,49:333-343 (1978).
Kandel, E.R. and Schwartz, J.H., ed.Principles of Neural Science,Chapter 2, pp. 14-23 Elsevier/North, Holland (1981).
Bloom, H.J.G.,Int. J. Radiat. Oncol. Biol. Phys.,8:1083-1087 (1982).
Chang, C.H., et al.,Cancer 52:997-1007 (1983).
Black, I., ed.Cellular and Molecular Biology of Neuronal Development,Chapter 2, pp. 29-47, Plenum Press, New York (1984).
Choucair, A.K., et al.,J. Neurosurg.,65:654-658 (1986).
Omata, T., et al.,J. Virol.,58:348-358 (1986).
A. Nomoto, et al.,Vaccines,6:134-137 (1988).
Kawamura, N., et al.,J. Virol.,63:1302-1309 (1989).
Agol, et al.,J. Virol.,63:4034-4038 (1989).
LaMonica, N. and Rancaniello. V.R.,J. Virol.,63:2357-2360 (1989).
Ren, R., et al.,Cell,63:353-362 (1990).
WHO Technical Report Series No. 80 (1990).
R. Altmeyer et al.,Virology,184:636-644 (1991).
Koike, S., et al.,PNAS,USA, 88:951-955 (1991).
Martuza, R.L., et al.,Science,252:854-856 (1991).
Miller, A.D.,Nature,357:455-460 (1992).
Minor, P.D.,Dev. Biol. Stand.,78:17-26 (1993).
Wimmer, E., et al.,Ann. Rev. Gen.,27:353-436 (1993).
Markert, J.M., et al.,Neurosurgery,32:597-603 (1993).
Wood, M.J.A., et al.,Gene Therapy,1:283-299 (1994).
L. Alexander et al.,PNAS,91:1406-1410 (1994).
Chen, S.H., et al.,PNAS,USA, 91:3054-3057 (1994).
Izquierdo, M., et al.,Gene Therapy,2:66-69 (1995).
Mineta T., et al.,Nature Medicineu,1:938-943 (1995).
Bischoff, J.R.,Science,274:373-376 (1996).
M. Gromeier et al.,Vaccines,96:19-25 (1996).
M. Gromeier et al.,PNAS,93:2370-2375 (1996).
H. Lu et al.,PNAS,93:1412-1417 (1996).
Fogh, J., et al.,J. Natl. Cancer Inst.,59:221-226 (1997).
Andreansky, S., et al.,Cancer Res.,57:1502-1509 (1997).
M. Gromeier et al.,J. of Neurovirology 3(1):35-38 (1997).
Bodian, D.,Diseases of the Nervous System.Chapter 170. pp. 2323-2339, McGraw Hill, New York.
Gromeier Matthias
Wimmer Eckard
Campell Bruce R.
Lucas Zachariah
Scully , Scott, Murphy & Presser, P.C.
The Research Foundation of State University of New York
LandOfFree
Recombinant poliovirus for the treatment of cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Recombinant poliovirus for the treatment of cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant poliovirus for the treatment of cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3694832